[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 3741748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 2705659, "exercisedValue": 0, "unexercisedValue": 112845}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "age": 45, "title": "Chief Technical Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 2987030, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kyle  Rasbach Ph.D., Pharm.D.", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  DiRisio", "title": "Senior Vice President of Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.27, "open": 3.32, "dayLow": 3.3, "dayHigh": 4.2086, "regularMarketPreviousClose": 3.27, "regularMarketOpen": 3.32, "regularMarketDayLow": 3.3, "regularMarketDayHigh": 4.2086, "payoutRatio": 0.0, "forwardPE": -1.400722, "volume": 1928790, "regularMarketVolume": 1928790, "averageVolume": 993315, "averageVolume10days": 822810, "averageDailyVolume10Day": 822810, "bid": 3.84, "ask": 3.92, "bidSize": 2, "askSize": 2, "marketCap": 128784576, "fiftyTwoWeekLow": 1.45, "fiftyTwoWeekHigh": 19.5, "fiftyDayAverage": 3.067, "twoHundredDayAverage": 6.08805, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 38337588, "profitMargins": 0.0, "floatShares": 24262447, "sharesOutstanding": 33191900, "sharesShort": 3114846, "sharesShortPriorMonth": 2939149, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0938, "heldPercentInsiders": 0.00753, "heldPercentInstitutions": 1.2110701, "shortRatio": 3.39, "shortPercentOfFloat": 0.1094, "impliedSharesOutstanding": 33191900, "bookValue": 2.655, "priceToBook": 1.4613937, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -109307000, "trailingEps": -3.31, "forwardEps": -2.77, "enterpriseToEbitda": -0.331, "52WeekChange": -0.7928457, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 3.88, "targetHighPrice": 28.0, "targetLowPrice": 10.0, "targetMeanPrice": 17.71429, "targetMedianPrice": 20.0, "recommendationMean": 1.42857, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 99831000, "totalCashPerShare": 3.008, "ebitda": -115665000, "totalDebt": 9399000, "quickRatio": 3.239, "currentRatio": 3.415, "debtToEquity": 10.667, "returnOnAssets": -0.42889, "returnOnEquity": -0.8065, "grossProfits": -75520000, "freeCashflow": -50433000, "operatingCashflow": -88000000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "fiftyDayAverageChange": 0.8130002, "fiftyDayAverageChangePercent": 0.26507995, "twoHundredDayAverageChange": -2.2080498, "twoHundredDayAverageChangePercent": -0.3626859, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "corporateActions": [], "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "postMarketChangePercent": -0.283509, "postMarketPrice": 3.869, "postMarketChange": -0.0110002, "regularMarketChange": 0.61, "regularMarketDayRange": "3.3 - 4.2086", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 993315, "fiftyTwoWeekLowChange": 2.43, "fiftyTwoWeekLowChangePercent": 1.6758621, "fiftyTwoWeekRange": "1.45 - 19.5", "fiftyTwoWeekHighChange": -15.62, "fiftyTwoWeekHighChangePercent": -0.8010256, "fiftyTwoWeekChangePercent": -79.28458, "earningsTimestamp": 1747047602, "earningsTimestampStart": 1747047602, "earningsTimestampEnd": 1747047602, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.31, "epsForward": -2.77, "epsCurrentYear": -2.55169, "priceEpsCurrentYear": -1.5205609, "postMarketTime": 1749252885, "regularMarketTime": 1749240001, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 18.6544, "regularMarketPrice": 3.88, "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]